Table 4.
Association of POLE EDMs with overall survival in clinical subgroups
| POLE mutation |
No POLE mutation |
Overall survival |
||||
|---|---|---|---|---|---|---|
| N | All deaths | N | All Deaths | Unadjusted HR (95% CI) | Adjusted HR (95% CI)1 | |
| <70 years | 27 | 9 (33%) | 174 | 44 (25%) | 1.41 (0.69–2.88) | 1.25 (0.60–2.63) |
| ≥70 years | 19 | 9 (47%) | 148 | 65 (44%) | 0.95 (0.47–1.91) | 1.72 (0.79–3.76) |
| Female | 15 | 5 (33%) | 125 | 55 (44%) | 0.82 (0.33–2.04) | 0.92 (0.36–2.35) |
| Male | 31 | 13 (42%) | 197 | 54 (27%) | 1.48 (0.81–2.71) | 1.65 (0.89–3.07) |
| Stages I+II | 24 | 4 (17%) | 160 | 29 (18%) | 0.83 (0.29–2.36) | 0.75 (0.26–2.19) |
| Stages III+IV | 22 | 14 (64%) | 162 | 80 (49%) | 1.42 (0.80–2.50) | 1.54 (0.85–2.78) |
| Grade 1 + 2 | 29 | 11 (38%) | 187 | 54 (29%) | 1.34 (0.70–2.57) | 1.87 (0.95–3.67) |
| Grade 3 + 4 | 13 | 7 (54%) | 85 | 38 (45%) | 1.14 (0.51–2.56) | 1.14 (0.49–2.70) |
| Colon, proximal | 13 | 6 (46%) | 85 | 34 (40%) | 1.17 (0.49–2.80) | 1.51 (0.62–3.73) |
| Colon, distal | 12 | 4 (33%) | 94 | 27 (29%) | 1.05 (0.37–3.01) | 1.24 (0.42–3.71) |
| Rectum | 21 | 8 (38%) | 140 | 45 (32%) | 1.19 (0.56–2.52) | 1.44 (0.65–3.20) |
| Chemotherapy, all stages | 20 | 14 (70%) | 129 | 60 (47%) | 1.84 (1.03–3.31) | 1.82 (0.99–3.34) |
| No chemotherapy, all stages | 26 | 4 (15%) | 192 | 48 (25%) | 0.54 (0.19–1.50) | 0.69 (0.24–1.96) |
| Chemotherapy, stages III+IV | 19 | 14 (74%) | 118 | 58 (49%) | 1.84 (1.03–3.32) | 1.87 (1.02–3.44) |
Statistical analysis accounts for late entry, that is, the potentially delayed time period between date of diagnosis and date of interview.
1
Adjusted for age, sex, stage at diagnosis, location of colorectal cancer (proximal colon/distal colon/rectum), adjuvant and neoadjuvant therapy.